Craxì A, Marino L, Aragona E, Patti C
Academic Dept. of Medicine, University of Palermo, Italy.
Boll Ist Sieroter Milan. 1988;67(4):275-82.
IgM antibody to hepatitis B core antigen (IgM anti-HBc) was determined in 348 subjects with hepatitis B virus infection, in order to evaluate, in an area of high hepatitis D virus (HDV) endemicity, its usefulness in discriminating acute HBV hepatitis from HDV superinfection of HBsAg carriers, and to see whether in chronic HBV infection IgM anti-HBc can be related to viral replication, disease activity, or risk of neoplastic transformation. The positive predictive value (PV) of IgM anti-HBc for acute hepatitis was low at the standard 2.1 cut-off (35.2%), but a cut-off of 7 raised the positive PV, retaining a negative PV of above 90% and a sensitivity of 59.5%. No significant relationship was found in chronic infection between IgM anti-HBc, the level of HBV replication or the type of liver disease. Patients with HDV infection were mostly IgM anti-HBc negative. Hepatocellular carcinoma was not associated with a raised prevalence of IgM anti-HBc.
对348例乙肝病毒感染患者检测了乙肝核心抗原IgM抗体(IgM抗-HBc),目的是在丁型肝炎病毒(HDV)高流行区评估其在鉴别急性HBV肝炎与HBsAg携带者HDV重叠感染方面的作用,以及观察在慢性HBV感染中IgM抗-HBc是否与病毒复制、疾病活动或肿瘤转化风险相关。在标准的2.1临界值时,IgM抗-HBc对急性肝炎的阳性预测值(PV)较低(35.2%),但临界值提高到7时,阳性PV升高,阴性PV保持在90%以上,敏感性为59.5%。在慢性感染中,未发现IgM抗-HBc、HBV复制水平或肝病类型之间存在显著关系。HDV感染患者大多IgM抗-HBc阴性。肝细胞癌与IgM抗-HBc患病率升高无关。